IMI Stakeholder forum

Industry priorities

Richard BERGSTRÖM
EFPIA Director General

Budapest, 12 May 2011
The European Union and the pharmaceutical industry have joined forces to make drug R&D processes in Europe more efficient and effective and enhance Europe’s competitiveness in the sector.
Make **drug R&D processes in Europe** more efficient and effective and enhance Europe’s **competitiveness in the sector**

To the benefit of EU:
1. Improved healthcare status of individuals and society and
2. Positive economical impact

To the benefit of Pharma Industry: facilitate development of next generation drugs
Make **drug R&D processes in Europe more efficient and effective** and enhance Europe’s **competitiveness in the sector**

**Vision**

**Primary focus of early IMI calls**

- Idea generation
- Basic research and non-clinical testing
- Human testing

**Primary focus if we want to make EU competitive**

- Regulatory approval and Health technology assessment
- Marketed drug
WHO report 2004:

1. Antibacterial drug resistance
2. Pandemic influenza
3. Cardiovascular disease secondary prevention
4. Diabetes
5. Cancer
6. Acute stroke
7. HIV/AIDS
8. Tuberculosis
9. Neglected diseases
10. Malaria
11. Alzheimer disease
12. Osteoarthritis
13. Chronic obstructive pulmonary disease (COPD)
14. Alcohol use disorders
15. Depression in the elderly and adolescents
Per definition (follows from our long-term business model):

Public health priorities = Industry priorities
Strategic direction:

* Better definition of priority needs
* Easier access to defined patients – and possibility to follow them
* Better tools in basic and non-clinical research
* Better alignment of expectations and requirements
* Better definition of “comparative effectiveness” – or what is added value

For FP8: focus on meeting public health needs, while supporting European R&D. More flexibility in terms of global allocation and industry/academic ratio.